Research Topics
| Sarah P ThayerSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesisSarah P Thayer
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Nature 425:851-6. 2003..These data suggest that this pathway may have an early and critical role in the genesis of this cancer, and that maintenance of hedgehog signalling is important for aberrant proliferation and tumorigenesis...
In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasiaOliver Strobel
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Gastroenterology 133:1999-2009. 2007..However, available studies are based on interpretation of static data rather than on direct evidence. Transdifferentiation from acinar to ductal cells has never been confirmed in the adult pancreas...- Novel xenograft and cell line derived from an invasive intraductal papillary mucinous neoplasm of the pancreas give new insights into molecular mechanismsStefan Fritz
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Pancreas 39:308-14. 2010..Little is known about the genetic signature of IPMC. In this study, we describe a novel xenograft model and cell culture created to biologically and genetically characterize these tumors... 
Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasiaOliver Strobel
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Gastroenterology 138:1166-77. 2010..A majority of PanIN are thought to arise from ducts. We identified a novel ductal compartment that is gathered in gland-like outpouches (pancreatic duct glands [PDG]) of major ducts and characterized its role in injury and metaplasia...- Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomesAlex B Haynes
Department of Surgery, Massachusetts General Hospital, Wang Ambulatory Care Center 460, 15 Parkman St, Boston, MA 02114, USA
Arch Surg 146:534-8. 2011..To describe the characteristics and outcomes after resection of incidentally discovered, nonfunctioning pancreatic endocrine tumors (PETs)... - Current trends in pancreatic cystic neoplasmsCristina R Ferrone
Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
Arch Surg 144:448-54. 2009..To define how patients with pancreatic cysts are being diagnosed and treated... - 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General HospitalNakul P Valsangkar
General and GI Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Surgery 152:S4-12. 2012..The objective of this study was to identify trends in the diagnosis and treatment of cystic neoplasms of the pancreas using a retrospective review of patients from a surgical database at an academic referral center during a 33-year period... - Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinomaStefan Fritz
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Ann Surg 249:440-7. 2009..To determine whether intraductal papillary mucinous neoplasms of the pancreas (IPMNs) have a different genetic background compared with ductal adenocarcinoma (PDAC)... - Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resectionJ Ruben Rodriguez
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Gastroenterology 133:72-9; quiz 309-10. 2007..This study describes the combined experience of 2 tertiary centers with branch-duct IPMNs aiming to validate these recommendations... - Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General HospitalMehrdad Nikfarjam
Department of Surgery, Massachusetts General Hospital Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
Ann Surg 247:165-72. 2008..To determine changes in the management strategy of patients with insulinomas and identify critical factors in patient outcome... - Quality of life in pancreatic cancer: analysis by stage and treatmentStefano Crippa
Wang Ambulatory Care Center 460, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA
J Gastrointest Surg 12:783-93; discussion 793-4. 2008..One-year survival was 74%, 30%, and 16% for groups 1, 2, and 3 respectively (p=0.001). Pancreatic cancer prognosis is still dismal. In addition to long-term survival benefits, surgery impacts favorably quality of life... - Pancreatic ductal adenocarcinoma: long-term survival does not equal cureCristina R Ferrone
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Surgery 152:S43-9. 2012..Our aim was to identify the prognostic factors for long-term survival after resection of pancreatic ductal adenocarcinoma related to patients, treatments, and tumor biology... - Incidental pancreatic cysts: do we really know what we are watching?Camilo Correa-Gallego
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Pancreatology 10:144-50. 2010..Most cystic neoplasms of the pancreas (CNPs) are incidentally discovered. Their management continues to be debated and preoperative diagnosis is often inaccurate... - Debridement and closed packing for sterile or infected necrotizing pancreatitis: insights into indications and outcomes in 167 patientsJ Ruben Rodriguez
Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Ann Surg 247:294-9. 2008..To examine the surgical indications and clinical outcomes of a large cohort of patients with necrotizing pancreatitis... - Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinomaIsmael Dominguez
Department of Surgery, Massachusetts General Hospital, Wang Ambulatory Care Center 460, 15 Parkman Street, Boston, Massachusetts 02114, USA
World J Surg 32:1051-6. 2008..High platelet counts are associated with an adverse effect on survival in various neoplastic entities. The prognostic relevance of preoperative platelet count in pancreatic cancer has not been clarified... - Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005Parsia A Vagefi
Department of Surgery, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
Arch Surg 142:347-54. 2007..To assess changing patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms (PNENs)... - Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?Ioannis T Konstantinidis
Department of Surgery, Massachusetts General Hospital, Boston, MA, USA
J Gastrointest Surg 14:261-7. 2010..Lymph node metastases are prognostically significant in pancreatic ductal adenocarcinoma. Little is known about the significance of direct lymph node invasion... - Implications and management of pancreatic fistulas following pancreaticoduodenectomy: the Massachusetts General Hospital experienceGregory Veillette
Department of Surgery, Massachusetts General Hospital, 15 Parkman St, Wang Ambulatory Care Center 460, Boston, MA 02114, USA
Arch Surg 143:476-81. 2008..To describe the management and impact of pancreatic fistulas in a high-volume center... - Evolution of the Whipple procedure at the Massachusetts General HospitalCarlos Fernandez-del Castillo
Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
Surgery 152:S56-63. 2012..The goal of this study was to investigate the evolution of pancreatoduodenectomy at the Massachusetts General Hospital (MGH)... - Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter?Deepika Nehra
Department of Surgery, Massachusetts General Hospital, Boston MA, USA
Pancreatology 12:358-63. 2012.... - Metastatic tumors in the pancreas in the modern eraIoannis T Konstantinidis
Department of Surgery, Massachusetts General Hospital, Boston, MA, USA
J Am Coll Surg 211:749-53. 2010..Our aim was to describe the clinicopathologic characteristics and patient outcomes in a modern series of patients who underwent metastasectomy, with an emphasis on RCC... - Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypesMari Mino-Kenudson
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Gut 60:1712-20. 2011..The authors investigate the clinicopathological characteristics and the impact on survival of both the invasive component and its background IPMN... - Targeting the MAGE A3 antigen in pancreatic cancerAlexandria P Cogdill
Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
Surgery 152:S13-8. 2012..The results of these studies have important translational implications and provide the rationale for combined treatment with chromatin remodeling agents and immunotherapeutic approaches for pancreatic cancer... - Distal pancreatectomy with splenic preservation revisitedJ Ruben Rodriguez
Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
Surgery 141:619-25. 2007..The purpose of this study was to examine the short-term implications of this operation, comparing it to the outcomes following distal pancreatectomy with splenectomy... - Pancreatic fistula rates after 462 distal pancreatectomies: staplers do not decrease fistula ratesCristina R Ferrone
Department of General Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
J Gastrointest Surg 12:1691-7; discussion 1697-8. 2008..Pancreatic fistula is a major source of morbidity after distal pancreatectomy (DP). We reviewed 462 consecutive patients undergoing DP to determine if the method of stump closure impacted fistula rates... - Identification of a novel kindred with familial pancreatitis and pancreatic cancerJennifer LaFemina
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Pancreatology 9:273-9. 2009..Multiple causative mutations have been identified. Here we describe a pancreatitis/pancreatic cancer (P/PC) family, which demonstrates pancreatitis and pancreatic cancer resulting from an uncharacterized mutation... - Plectin-1 as a novel biomarker for pancreatic cancerDirk Bausch
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114 2622, USA
Clin Cancer Res 17:302-9. 2011..Plectin-1 (Plec1) was recently identified as one such biomarker. However, its suitability as a specific biomarker for human pancreatic cancer, and its usability as an imaging target, remain to be assessed... - Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinomaCristina R Ferrone
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J Clin Oncol 24:2897-902. 2006..CA19-9 levels should be included in a patient's perioperative care and should be considered for prognostic nomograms... - Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasmsDirk Bausch
Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 2622, USA
J Gastrointest Surg 13:1948-54; discussion 1954. 2009..Improved detection of malignancy using novel biomarkers may therefore improve diagnostic accuracy. One such promising novel biomarker is Plectin-1 (Plec-1)... - Implications and cost of pancreatic leak following distal pancreatic resectionJ Ruben Rodriguez
Center for Clinical Effectiveness in Surgery, Harvard Medical School, Boston, USA
Arch Surg 141:361-5; discussion 366. 2006..We sought to provide an economic framework for potential interventions aimed at reducing its occurrence... - Beta cell transdifferentiation does not contribute to preneoplastic/metaplastic ductal lesions of the pancreas by genetic lineage tracing in vivoOliver Strobel
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Proc Natl Acad Sci U S A 104:4419-24. 2007.... - Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitisGuido Alsfasser
Department of Surgery and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Arch Surg 141:670-6; discussion 676-7. 2006..Drotrecogin treatment reduces inflammation in the pancreas and lungs and significantly improves survival. These results encourage clinical investigation of drotrecogin in the treatment of severe AP... - Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft modelAlexander R Guimaraes
Department of Radiology, Center for Molecular Imaging Research, Massachusetts General Hospital, Charlestown, MA, USA
Pancreas 37:440-4. 2008..We tested whether magnetic resonance imaging measures of vascular volume fraction (VVF) using magnetic iron oxide nanoparticles are sensitive to the antiangiogenic effect of targeted Shh therapies in a PDAC xenograft model... - Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survivalCristina R Ferrone
Memorial Sloan Kettering Cancer Center, Department of Surgery, 1275 York Ave, Box 435, New York, NY 10021, USA
J Clin Oncol 23:7529-35. 2005..A single US institution database was used to test the validity of the pancreatic adenocarcinoma nomogram established at Memorial Sloan-Kettering Cancer Center... - Management of mucin-producing cystic neoplasms of the pancreasStefan Fritz
Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
Oncologist 14:125-36. 2009..The present work offers an overview of current and generally accepted clinical guidelines for the diagnosis and treatment of IPMNs and MCNs... - Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patientsCarlos Fernandez-del Castillo
Department of Surgery and Gastroenterology, Massachusetts General Hospital ACC 336, 15 Parkman Street, Boston, MA 02114, USA
Arch Surg 138:427-3; discussion 433-4. 2003..Widespread use of computed tomography and ultrasound has led to the identification of increasing numbers of patients with asymptomatic cystic lesions of the pancreas... - Epithelial cell guidance by self-generated EGF gradientsCally Scherber
Surgical Services and BioMEMS Resource Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Integr Biol (Camb) 4:259-69. 2012..Better understanding of the UTC self-guidance strategy could eventually help devise new ways for modulating epithelial cell migration and delaying cancer cell invasion or accelerating wound healing... - PancreaticoduodenectomyAndrew L Warshaw
Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114-2696, USA
J Gastrointest Surg 8:733-41. 2004 - Imaging of acute mesenteric ischemia using multidetector CT and CT angiography in a porcine modelDavid E Rosow
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
J Gastrointest Surg 9:1262-74; discussion 1274-5. 2005..These results indicate that M.D.CT-CTA holds great promise for the early detection necessary for successful treatment of acute mesenteric ischemia... - PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine networkHaoqiang Ying
Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA 02215, USA
Cancer Discov 1:158-69. 2011..Thus, PTEN/phosphoinositide 3-kinase (PI3K) pathway alteration is a common event in PDAC development and functions in part to strongly activate the NF-κB network, which may serve to shape the PDAC tumor microenvironment... - Complete dorsal pancreatectomy with preservation of the ventral pancreas: a new surgical techniqueSarah P Thayer
Department of Surgery, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
Surgery 131:577-80. 2002 - Added value of selected images embedded into radiology reports to referring cliniciansVeena R Iyer
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
J Am Coll Radiol 7:205-10. 2010..The aim of this study was to evaluate the added utility of embedding images for findings described in radiology text reports to referring clinicians... - Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomasEunice L Kwak
Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
Clin Cancer Res 12:4283-7. 2006..Given recent reports of TKI-responsive cases of esophageal and pancreatic cancer, this study was designed to determine the prevalence of EGFR mutations in these gastrointestinal cancers... - Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resectionRoberto Salvia
Department of Surgery, University of Verona, Verona, Italy
Ann Surg 239:678-85; discussion 685-7. 2004..These findings support both the concept of progression of benign IPMNs to invasive cancer and an aggressive policy of resection at diagnosis... - Middle pancreatectomy: indications, short- and long-term operative outcomesStefano Crippa
Department of Surgery, Policlinico GB Rossi, University of Verona, Verona, Italy
Ann Surg 246:69-76. 2007..To evaluate the indications, perioperative, and long-term outcomes of a large cohort of patients who underwent middle pancreatectomy (MP)... - Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patientsStefano Crippa
Department of Surgery, University of Verona, Verona, Italy
Ann Surg 247:571-9. 2008..We evaluated the clinicopathologic characteristics, prevalence of cancer, and prognosis of a large series of well-characterized MCNs in 2 tertiary centers...
Research Grants
- The Hedgehog Pathway and Pancreatic NeoplasiaSarah Thayer; Fiscal Year: 2007..This will allow us to better understand the role of this pathway in human pancreatic cancer, so that it may be exploited for new diagnostic and therapeutic modalities. ..